Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.22.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.22.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.22.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.22.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FE.1.2ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FE.1.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FE.1.2NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FE.1.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FE.1.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FE.1.2NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FE.1.2NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FE.1.2ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBL.3ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBL.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBL.3NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBL.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBL.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBL.3NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBL.3NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBL.3ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.5.56ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.5.56ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.56NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.5.56NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.56NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.56NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.56NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.5.56ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.16.3ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.16.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.16.3NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.16.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.16.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.16.3NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.16.3NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.16.3ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
EG.1.8ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
EG.1.8ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
EG.1.8NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
EG.1.8NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
EG.1.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
EG.1.8NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
EG.1.8NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
EG.1.8ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.5.49ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.5.49ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.49NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.5.49NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.49NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.49NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used